Ubiquitous Pharmacogenomics (U-PGx)
  • Home
  • U-PGx
    • U-PGx Consortium
    • Work Packages
    • Deliverables
    • U-PGx Publications
    • Ethics
    • Scientific Advisory Board
  • PREPARE
    • Study Overview
    • Results
    • Pharmacogenomics guidelines (DPWG)
    • FAQ
    • Downloads & Web Resources
    • LIM Survey
    • Data Collection
    • Ethics
  • Education
    • Education material
    • Events Calendar
    • Upcoming U-PGx Events
    • Past U-PGx Events
    • Links
    • Other PGx Organizations
      • PGRN
  • News
  • Login Members
  • Contact

Author: Wendy van Hemmen

Comprehensive overview of the pharmacogenetic diversity in Ashkenazi Jews. Zhou Y, Lauschke VM. J Med Genet. 2018 Sep;55(9):617-627.

Posted on May 15, 2019 by Wendy van Hemmen

Continue reading →

Posted in Publications

Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation. Cecchin E, De Mattia E, Ecca F, Toffoli G. Drug Resist Updat. 2018 Jul;39:18-40.

Posted on May 15, 2019 by Wendy van Hemmen

Continue reading →

Posted in Publications

From hype to reality: data science enabling personalized medicine. Fröhlich H, et al. BMC Med. 2018 Aug 27;16(1):150.

Posted on May 15, 2019 by Wendy van Hemmen

Continue reading →

Posted in Publications

Personalized laboratory medicine: a patient-centered future approach. Prodan Žitnik I, et al.; behalf of EFLM/ESPT working group of Personalised Laboratory Medicine on. Clin Chem Lab Med. 2018 Nov 27;56(12):1981-1991.

Posted on May 15, 2019 by Wendy van Hemmen

Continue reading →

Posted in Publications

Drinking Ethanol Has Few Acute Effects on CYP2C9, CYP2C19, NAT2, and P-Glycoprotein Activities but Somewhat Inhibits CYP1A2, CYP2D6, and Intestinal CYP3A: So What? Gazzaz M, et al. Clin Pharmacol Ther. 2018 Dec;104(6):1249-1259.

Posted on May 15, 2019 by Wendy van Hemmen

Continue reading →

Posted in Publications

Improving decision making on DPYD and UGT1A1*28 patients’ profiling with an innovative reimbursement strategy. Roncato R, Cecchin E, Toffoli G. Pharmacogenomics. 2018 Mar;19(4):301-304.

Posted on May 15, 2019 by Wendy van Hemmen

Continue reading →

Posted in Publications

How to Consider Rare Genetic Variants in Personalized Drug Therapy. Lauschke VM, Ingelman-Sundberg M. Clin Pharmacol Ther. 2018 May;103(5):745-748.

Posted on May 15, 2019 by Wendy van Hemmen

Continue reading →

Posted in Publications

CPIC Guideline for CYP2D6 and Tamoxifen Therapy. Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, Caudle KE, Klein TE. Clin Pharmacol Ther. 2018 May;103(5):770-777.

Posted on May 15, 2019 by Wendy van Hemmen

Continue reading →

Posted in Publications

Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). Bergmeijer TO, et al.; ICPC Investigators. Am Heart J. 2018 Apr;198:152-159.

Posted on May 15, 2019 by Wendy van Hemmen

Continue reading →

Posted in Publications

Systemic regulation of bilirubin homeostasis: Potential benefits of hyperbilirubinemia. Fujiwara R, Haag M, Schaeffeler E, Nies AT, Zanger UM, Schwab M. Hepatology. 2018 Apr;67(4):1609-1619.

Posted on May 15, 2019 by Wendy van Hemmen

Continue reading →

Posted in Publications

Posts navigation

← Older posts
Newer posts →

Recent Posts

  • Matching medication to DNA leads to 30% fewer side effects
  • U-PGx Personalized Medicine Symposium
  • bio.logis receives the E-Health Award Hessen 2021
  • 7th U-PGx Personalized Medicine Day
  • Dr. Cristina Lucía Dávila Fajardo obtains PhD degree in pharmacogenetics
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 668353.